The NeurologyLive® MS Disease Spotlight page offers specific updates and coverage on the latest expert conversations and data readouts related to the treatment and management of patients with multiple sclerosis and demyelinating disorders.
October 28th 2024
A clinician’s guide to using a personalized medicine approach to monitor cognition in MS.
Sustained Reductions of Brain Atrophy Observed With S1P Modulator Ozanimod
September 21st 2024In the original phase 3 studies, treatment with ozanimod resulted in significant reductions in clinical relapses and lesion counts on MRI as well as slowed brain volume loss relative to intramuscular interferon-β-1a.
Important Changes Are Coming to Medicare in 2025: What You Need to Know to Help Your Patients
September 19th 2024Nicole M. Boschi, PhD, the director of regulatory affairs at the National MS Society, talked about the impact of the upcoming Medicare Part D and Medicare Advantage changes for the multiple sclerosis community.
2024 Revisions to McDonald Diagnostic Criteria for Multiple Sclerosis: Peter Calabresi, MD
September 19th 2024The codirector of the Precision Medicine MS Center at Johns Hopkins University discussed the new updates to the MS diagnostic criteria presented at the 40th ECTRIMS Congress in Copenhagen. [WATCH TIME: 5 minutes]
Evolving Understanding and Treatment of Smoldering Multiple Sclerosis: Antonio Scalfari, MD, PhD
September 15th 2024The consultant neurologist at Imperial College Healthcare Trust discussed how smoldering MS challenges traditional views of disease progression, seeking combined therapies targeting both inflammatory activity and mechanisms driving smoldering-associated worsening. [WATCH TIME: 4 minutes]
The Importance of Addressing Unmet Treatment Needs in Smoldering MS: Antonio Scalfari, MD, PhD
September 13th 2024The consultant neurologist at Imperial College Healthcare Trust highlighted the importance of acknowledging smoldering multiple sclerosis, urging a shift in therapeutic focus beyond relapses and advocating for a new approach to disease management. [WATCH TIME: 5 minutes]
Understanding Smoldering Disease in MS Beyond Focal Inflammatory Activity: Antonio Scalfari, MD, PhD
September 10th 2024The consultant neurologist at Imperial College Healthcare Trust talked about how smoldering disease in multiple sclerosis encompasses disease progression independent of relapsing activity, thus broadening the scope beyond traditional measures. [WATCH TIME: 4 minutes]